Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics

Osteoporos Int. 2015 Dec 22. [Epub ahead of print]

Studies are urgently needed to i) prove the underlying pathophysiological processes suggested above, ii) establish the predictive criteria exposing patients to an increased risk of RVF, and iii) determine appropriate treatment regimens to be applied in such patients.

Autor: Popp AW, Zysset PK, Lippuner K.
Patrocinadores de la web
Lilly
Angelini
Laboratorios Rubió
Grupo Italfármaco
UCB-Pharma
Theramex
Stada
Gedeon Richter
Kyowa Kirin
Amgen
Gebro